Goldman Sachs
GERM

Goldman Sachs’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

Goldman Sachs’s Portfolio GERM Stock Details GERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,372
Closed -$203K – 6009
2023
Q4 		$203K Sell
10,372
-27,168
-72% -$474K ﹤0.01% 5147
2023
Q3 		$672K Sell
37,540
-25,386
-40% -$496K ﹤0.01% 4499
2023
Q2 		$1.3M Buy
62,926
+32,376
+106% +$678K ﹤0.01% 4172
2023
Q1 		$625K Sell
30,550
-34,266
-53% -$767K ﹤0.01% 4707
2022
Q4 		$1.45M Buy
64,816
+26,682
+70% +$601K ﹤0.01% 4169
2022
Q3 		$791K Buy
38,134
+11,074
+41% +$269K ﹤0.01% 4680
2022
Q2 		$629K Sell
27,060
-45,638
-63% -$1.09M ﹤0.01% 4923
2022
Q1 		$1.99M Buy
72,698
+27,295
+60% +$769K ﹤0.01% 4265
2021
Q4 		$1.62M Sell
45,403
-798
-2% -$29.9K ﹤0.01% 4421
2021
Q3 		$1.9M Buy
46,201
+27,649
+149% +$1.17M ﹤0.01% 4253
2021
Q2 		$742K Sell
18,552
-10,709
-37% -$399K ﹤0.01% 4976
2021
Q1 		$1.04M Hold
29,261
– – ﹤0.01% 4578
2020
Q4 		$910K Hold
29,261
– – ﹤0.01% 4255
2020
Q3 		$809K Buy
+29,261
New +$860K ﹤0.01% 4220

Other funds holding GERM

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
CHC
City Holding Co Charleston, West Virginia $884M AUM 27.52% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
TAM
Tucker Asset Management Littleton, Colorado $405M AUM 27.41% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

Goldman Sachs's GERM Position: Q1 2024 in Review

Goldman Sachs sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q1 2024, closing a stake of 10,372 shares — an estimated $203K sold.

Goldman Sachs first reported a position in GERM in Q3 2020 and held it in 14 quarters. The position peaked at $1.99M in Q1 2022. 11 funds tracked by Wall St. Rank hold GERM as of Q1 2024.

  • Goldman Sachs reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q1 2024 after selling out during the quarter.
  • Goldman Sachs sold 10,372 Amplify Treatments, Testing and Advancements ETF shares in Q1 2024, an estimated $203K.
  • Goldman Sachs first reported a position in Amplify Treatments, Testing and Advancements ETF in Q3 2020 and held it in 14 quarters.
  • Goldman Sachs's Amplify Treatments, Testing and Advancements ETF position peaked at $1.99M in Q1 2022.
  • 11 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q1 2024.

Based on Goldman Sachs's 13F filing for Q1 2024, filed 15 May 2024.